NCT04663412

Brief Summary

The potential of the administration of indocyanine green (ICG) allows the execution of SLN biopsy, avoiding the multiple administrations of radiocolloid in the pre-operative phase, painful for the patient, elimination, and exposure to radioactivity. Therefore, while requiring standardization of the methodology and a large-scale application, this procedure could open a new surgical management perspective in patients with early-stage vulvar cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 9, 2020

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 1, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 11, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 20, 2021

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2023

Completed
Last Updated

December 11, 2020

Status Verified

December 1, 2020

Enrollment Period

1 year

First QC Date

December 1, 2020

Last Update Submit

December 6, 2020

Conditions

Keywords

vulvar cancerindocyanine greensentinel nodesurgerysingle center

Outcome Measures

Primary Outcomes (1)

  • Progression-free survival

    The length of time during and after the treatment of vulvar cancer with sentinel node, that a patient lives with the disease but it does not get worse.

    3 years

Secondary Outcomes (1)

  • Overall Survival

    3 years

Study Arms (1)

Patients FIGO IB stage

EXPERIMENTAL

Vulvar Cancer IB stage

Other: Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)

Interventions

Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.

Patients FIGO IB stage

Eligibility Criteria

Age20 Years - 100 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients diagnosed with vulvar squamous cell carcinoma FIGO IB stage

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ginecologia e Ostetricia

Catania, 95126, Italy

RECRUITING

MeSH Terms

Conditions

Vulvar Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsVulvar DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Paolo Scollo, Prof.

    A.O.E. Cannizzaro

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Paolo Scollo, Prof.

CONTACT

Martina Ferrara, Dr.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 1, 2020

First Posted

December 11, 2020

Study Start

July 9, 2020

Primary Completion

July 20, 2021

Study Completion

July 20, 2023

Last Updated

December 11, 2020

Record last verified: 2020-12

Locations